文献速递前列腺癌

前列腺癌局灶激光消融:磁共振-超声融合引导的可行性

Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance.
PubMed 文献 · J Urol · 2017-04-08

这项前瞻性机构审查委员会批准的初步研究纳入11例中危前列腺癌患者,评估在泌尿外科门诊(磁体室外)以磁共振-超声融合引导行局灶激光消融的安全性与可行性。10例在局部麻醉下成功完成,平均手术时间95分钟,治疗后磁共振均见局限无灌注区,无CTCAE 3级及以上不良事件,6个月融合活检显示3例无癌、3例微小Gleason 3+3、4例持续中危前列腺癌。

要点

  • 11例中危前列腺癌患者中10例在局部麻醉下成功完成磁体室外局灶激光消融。
  • 无CTCAE 3级及以上不良事件,泌尿及性功能未见变化。
  • 6个月融合活检示3例无癌、3例微小Gleason 3+3、4例持续中危前列腺癌。

核心结论

  • 在泌尿外科门诊以磁共振-超声融合引导并热探头监测、局部麻醉下行前列腺癌局灶激光消融看起来安全且可行。
  • 需进一步开发以完善磁体室外局灶激光消融,并需额外研究确定合适的治疗边缘与肿瘤学疗效。

研究设计与样本

  • 前瞻性、机构审查委员会批准的初步研究,共纳入11例中危前列腺癌男性。
  • 以磁共振-超声融合引导经直肠将激光纤维置入含中危前列腺癌的兴趣区,插入热探头实时监测激光激活期间前列腺内温度。
  • 治疗后即刻及6个月行多参数磁共振(3特斯拉)并联合融合活检。

主要发现

  • 11例患者中10例在局部麻醉下成功治疗。
  • 平均手术时间95分钟(范围71至105)。
  • 治疗后磁共振显示全部10例均出现局限无灌注区,平均区域体积4.3 cc(范围2.1至6.0)。
  • 未发生CTCAE 3级及以上不良事件,泌尿或性功能未见变化。
  • 6个月时治疗部位磁共振-超声融合活检显示3例无癌、另3例微小Gleason 3+3、4例持续中危前列腺癌。

临床怎么用

  • 原文结论认为该操作在局部麻醉下于泌尿外科门诊以磁共振-超声融合引导并热探头监测看起来安全且可行。
  • 原文指出需进一步开发以完善磁体室外局灶激光消融,并需额外研究确定合适的治疗边缘与肿瘤学疗效。

局限性

  • 原文指出需进一步开发以完善磁体室外局灶激光消融。
  • 原文指出需额外研究确定合适的治疗边缘与肿瘤学疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Focal laser ablation is a potential treatment in some men with prostate cancer. Currently focal laser ablation is performed by radiologists in a magnetic resonance imaging unit (in bore). We evaluated the safety and feasibility of performing focal laser ablation in a urology clinic (out of bore) using magnetic resonance imaging-ultrasound fusion for guidance. MATERIALS AND METHODS: A total of 11 men with intermediate risk prostate cancer were enrolled in this prospective, institutional review board approved pilot study. Magnetic resonance imaging-ultrasound fusion was used to guide laser fibers transrectally into regions of interest harboring intermediate risk prostate cancer. Thermal probes were inserted for real-time monitoring of intraprostatic temperatures during laser activation. Multiparametric magnetic resonance imaging (3 Tesla) was done immediately after treatment and at 6 months along with comprehensive fusion biopsy. RESULTS: Ten of 11 patients were successfully treated while under local anesthesia. Mean procedure time was 95 minutes (range 71 to 105). Posttreatment magnetic resonance imaging revealed a confined zone of nonperfusion in all 10 men. Mean zone volume was 4.3 cc (range 2.1 to 6.0). No CTCAE grade 3 or greater adverse events developed and no changes were observed in urinary or sexual function. At 6 months magnetic resonance imaging-ultrasound fusion biopsy of the treatment site showed no cancer in 3 patients, microfocal Gleason 3 + 3 in another 3 and persistent intermediate risk prostate cancer in 4. CONCLUSIONS: Focal laser ablation of prostate cancer appears safe and feasible with the patient under local anesthesia in a urology clinic using magnetic resonance imaging-ultrasound fusion for guidance and thermal probes for monitoring. Further development is necessary to refine out of bore focal laser ablation and additional studies are needed to determine appropriate treatment margins and oncologic efficacy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Natarajan S, Jones TA, Priester AM, et al. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. J Urol. 2017. PMID: 28396184. doi:10.1016/j.juro.2017.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。